何霆

Beijing Imunopharm Technology Co., Ltd. was established in 2015 and is headquartered in Beijing. With the mission of "Make Cancer No Longer Incurable", Imunopharm is committed to applying innovative gene cell drug technology to the treatment of malignant tumors. Up to now, it has completed 9 rounds of strategic financing. With a one-stop independent R&D and industrialization platform for gene cell drugs and mastering core technologies such as scale-up plasmid preparation, lentiviral vector preparation, primary immune cell preparation, etc., Imunopharm has won the top prize in the finals of the National Disruptive Technology Innovation Competition, and has been approved three clinical trial approval notices issued by the National Medical Products Administration and the first gene Drug Production License for cell drug in Beijing. The company has become a leading innovation platform in the field of domestic independent gene cell drugs, with the research and development system covering blood tumors such as lymphoma, leukemia, and myeloma, and solid tumors such as liver cancer, colorectal cancer, gastric cancer, and pancreatic cancer. Qualifications such as the Ministry of Science and Technology of China - Key R&D Program Special Project, Beijing Major Science and Technology Project, and Postdoctoral Research Station, National High-tech Enterprise. On February 2023, the frontier CAR-T technology project of Imunopharm, as a key candidate with great potential, was recommended by the municipality to the finals of the 2022 National Disruptive Technology Innovation Competition, successfully won the winning award (the highest award), and was recommended to the Disruptive Technology Candidate Library of the Ministry of Science and Technology.